<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19677" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Codeine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Peechakara</surname>
            <given-names>Basil V.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tharp</surname>
            <given-names>Jack G.</given-names>
          </name>
          <aff>Univ of Mississippi Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Eriator</surname>
            <given-names>Ike I.</given-names>
          </name>
          <aff>University of Mississippi Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Mohit</given-names>
          </name>
          <aff>Cleveland Clinic Foundation</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Basil Peechakara declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jack Tharp declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ike Eriator declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohit Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19677.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Codeine&#x000a0;is a member of the opioid class of medications and is used to manage pain. Codeine is also used to treat cough. For mild-to-moderate pain, codeine is often used as a combined medication with acetaminophen or with an NSAID like ibuprofen.&#x000a0;The drug is often available as a combination product with promethazine or an NSAID like salicylic acid for cough and cold. Codeine is often marketed in the form of tablets and syrups. While opioids are valuable agents for treating pain, they also carry a high risk of misuse, abuse, addiction, and increased mortality, as&#x000a0;demonstrated by the current opioid epidemic and accompanying overdose deaths. This activity outlines the indications, mechanism of action, contraindications, adverse events, and other important aspects relating to the use of codeine in the clinical setting. The use of codeine by interprofessional team members relates to the potential for opioid misuse and the associated consequences, along with the appropriate indications.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between appropriate and inappropriate candidates for codeine therapy, considering factors like age, medical history, and potential drug interactions.</p></list-item><list-item><p>Screen patients for risk factors of opioid misuse, abuse, or addiction before initiating codeine therapy.</p></list-item><list-item><p>Assess the patient's response to codeine therapy, including pain relief, adverse effects, and any signs of misuse or addiction.</p></list-item><list-item><p>Implement collaboration&#x000a0;within&#x000a0;an interprofessional&#x000a0;team to develop comprehensive pain management plans that address individual needs while minimizing the risks associated with codeine use.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19677&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19677">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19677.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Codeine is an analgesic classified as a natural opioid because of its presence in opium from the poppy plant. Codeine is on the World Health Organization (WHO) list of essential adult medicines but was removed for children in 2011. Codeine is the most commonly taken opioid medication, judging by the number of countries where&#x000a0;it is used worldwide.<xref ref-type="bibr" rid="article-19677.r1">[1]</xref>&#x000a0;Patients do not usually perceive&#x000a0;codeine as harmful. While codeine is available as an over-the-counter (OTC) medication in several countries, including Denmark, Japan, Poland, and the United Kingdom, it is a prescription medication in others like the USA and Australia.<xref ref-type="bibr" rid="article-19677.r2">[2]</xref></p>
        <p>As a combination product, codeine falls into class III &#x02013; V of the Controlled Substance Schedule in the USA. In pure form, codeine is a Schedule II opioid. Codeine dependence is responsible for about 2% of admissions to substance abuse centers. The street names include little c, Cody, Captain Cody, lean, and Schoolboy. Codeine syrup can be mixed with soft drinks and goes by Texas tea, sizzurp, and purple drank. Codeine can also serve as a substrate for the illicit synthesis of desomorphine (krokodil).&#x000a0;</p>
        <p>Codeine (3-methylmorphine) is similar to morphine, but a methyl group is substituted for the hydroxyl group on the number 3 carbon of the morphine molecule. Codeine is an agonist at the&#x000a0;3 classic opioid receptors (Mu, delta, and kappa). Still, it has 20 times more affinity for the mu receptor when compared to the delta and possesses significantly less selectivity for the kappa receptor. As a combination product, codeine in low doses is effective for treating acute pain.<xref ref-type="bibr" rid="article-19677.r3">[3]</xref>&#x000a0;For mild to moderate pain, codeine is often used as a combined medication with paracetamol or with an NSAID like ibuprofen. Codeine is often available as a combination product with promethazine or an NSAID like salicylic acid for cough and cold. Codeine is often marketed in the form of tablets and syrups. The&#x000a0;main clinical indications are pain and cough.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Pain (mild-moderate): Codeine plays a role in treating mild to moderate pain, both acute and chronic.; its use is recognized in chronic pain due to ongoing cancer and palliative care. However, the use of codeine to treat other types of chronic pain remains controversial. Chronic pain is defined by the International Association for the Study of Pain as pain persisting beyond the standard tissue healing time of&#x000a0;3 months.<xref ref-type="bibr" rid="article-19677.r4">[4]</xref></p>
        <p>The most prevalent causes of non-cancer chronic pain include back pain, fibromyalgia, osteoarthritis, and headache. The drug's use in the management of acute pain likewise remains contentious, as evidenced by the inconclusive or equivocal findings in several recent randomized controlled trials when compared to common non-opioid OTC medications<xref ref-type="bibr" rid="article-19677.r5">[5]</xref><xref ref-type="bibr" rid="article-19677.r6">[6]</xref><xref ref-type="bibr" rid="article-19677.r1">[1]</xref></p>
        <p>Care&#x000a0;is needed when prescribing codeine.<xref ref-type="bibr" rid="article-19677.r7">[7]</xref>&#x000a0;</p>
        <p>This includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Before initiating codeine therapy, clinicians must perform a history, physical examination, and essential testing, including assessing the risk of substance addiction, misuse, or abuse.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clinicians must consider codeine as an option if the pain has a deleterious effect on the quality of life and the benefits of the therapy outweigh the potential risks.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The clinicians and patients must discuss initial treatment with codeine as a therapeutic trial to determine whether the therapy is appropriate.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A&#x000a0;risk-benefit evaluation is necessary on an ongoing basis with the therapy.</p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA-Approved Indications</bold>
</p>
        <p>Cough: Codeine is useful in treating various etiologies producing chronic cough. Chronic cough can derive from various pathological states, with codeine being variably effective at treating the cough depending on the underlying etiology.<xref ref-type="bibr" rid="article-19677.r8">[8]</xref><xref ref-type="bibr" rid="article-19677.r9">[9]</xref> Although&#x000a0;codeine has been shown to decrease cough frequency and severity in these patients, other medications like dextromethorphan have been shown in some studies to be superior antitussives and preferred by patients.<xref ref-type="bibr" rid="article-19677.r10">[10]</xref><xref ref-type="bibr" rid="article-19677.r1">[1]</xref>&#x000a0;</p>
        <p>Restless leg syndrome: Codeine treats refractory restless leg syndrome (RLS) at night. However, the dose prescribed should be low, and patients&#x000a0;should be non-responders to all other standard treatment protocols for RLS.<xref ref-type="bibr" rid="article-19677.r11">[11]</xref></p>
        <p>Persistent diarrhea (palliative):<bold>&#x000a0;</bold>Codeine and loperamide are equally effective for this indication. Assessment by the&#x000a0;clinician&#x000a0;and weighing the possibly addictive potential of codeine against the higher cost of loperamide, as well as an individual&#x000a0;difference in patient's vulnerability to adverse effects, help determine whether codeine or loperamide is a better choice.<xref ref-type="bibr" rid="article-19677.r12">[12]</xref><xref ref-type="bibr" rid="article-19677.r1">[1]</xref></p>
      </sec>
      <sec id="article-19677.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Codeine is a prodrug metabolized by cytochrome P450 2D6 to morphine which mediates most of the analgesic effects of codeine in the body. Over 100 variants of this enzyme (CYP2D6) result in a continuum of activity. The effects of codeine are primarily dictated by the specific subtype (ultrafast metabolizers vs poor metabolizers) of the polymorphic enzyme CYP2D6 present within the individual.<xref ref-type="bibr" rid="article-19677.r13">[13]</xref></p>
        <p>Ultra-rapid metabolizers can have high concentrations of morphine following the administration of codeine. About&#x000a0;3% of African-Americans, 1% to 10% of the White population, and 11% to 30% of North Africans are ultra-rapid metabolizers.<xref ref-type="bibr" rid="article-19677.r1">[1]</xref> Children who are ultrarapid metabolizers have died following the administration of codeine.<xref ref-type="bibr" rid="article-19677.r14">[14]</xref></p>
        <p>Opioid-induced infant deaths have occurred from breastfeeding by mothers who were ultrarapid metabolizers taking codeine postpartum. Conversely, poor metabolizers may&#x000a0;experience&#x000a0;poor pain relief when treated with codeine. The presence of the methyl group on the number 3 carbon limits the first-pass presystemic metabolism of codeine in the liver. This increases the availability of codeine following oral administration. The difference between the oral and parental doses of codeine is much smaller than that of other opioids like morphine.<xref ref-type="bibr" rid="article-19677.r2">[2]</xref>&#x000a0;</p>
        <p><bold>Absorption:</bold> Codeine is absorbed from the gastrointestinal tract almost completely (94%), and maximum plasma concentration (Cmax) is achieved after&#x000a0;1 hour.<xref ref-type="bibr" rid="article-19677.r14">[14]</xref> Administration of codeine every&#x000a0;4 hours results in steady-state concentration in 48 hours. Most foods do not significantly affect the absorption of codeine.</p>
        <p><bold>Distribution:</bold>&#x000a0;Codeine has an apparent volume of distribution of 3 to 6 L/kg, suggesting extensive tissue distribution.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Codeine is metabolized by conjugation to morphine (5% to 10%) and N-demethylation to norcodeine (approximately 10%). CYP2D6 is the principal enzyme responsible for transforming codeine to morphine, and P450 3A4 (CYP3A4) is the major enzyme for converting codeine to norcodeine.<xref ref-type="bibr" rid="article-19677.r14">[14]</xref>&#x000a0;CYP2D6 inhibitors (for instance, bupropion, fluoxetine, paroxetine, and quinidine) can lead to a decreased level of morphine from codeine metabolism and decrease the analgesic effect following treatment with codeine. Concomitant use with CYP3A4 inhibitors (for instance, macrolide antibiotics, protease inhibitors, and azole antifungal agents) can increase metabolism through the CYP2D6 pathway and thus increase the availability of morphine from treatment with codeine. Conversely, concomitant use with CYP3A4 inducers (for instance, carbamazepine, phenytoin, and rifampicin) can increase norcodeine levels and lower levels of morphine byproduct. Codeine exhibits first-order kinetics in that its rate of metabolism is proportional to the concentration of drug available in plasma.<xref ref-type="bibr" rid="article-19677.r15">[15]</xref>&#x000a0;Codeine 6 glucuronide may also cause analgesia. Due to differences in metabolism, the analgesic effects can vary from one individual to another.</p>
        <p><bold>Excretion:</bold>&#x000a0;Approximately 90% of codeine is excreted by the kidney, of which approximately 10% is unchanged. The t&#x000bd; of codeine and its metabolites is about 3 hours.</p>
        <p><bold>Pharmacodynamics:</bold> Classically, 3 main opioid receptors are recognized, although other subtypes exist. These are all G-protein coupled and&#x000a0;originally named mu, delta, and kappa.<xref ref-type="bibr" rid="article-19677.r16">[16]</xref> When opioids bind to these receptors, a series of intracellular events occur, resulting in decreased intracellular cAMP, hyperpolarization of the cell and neuronal cells, and inhibition of the release of nociceptive neurotransmitters.</p>
        <p>Within the nervous system, activation of mu receptors in the midbrain is the dominant mechanism of opioid-induced analgesia. The cough reflex is primarily mediated through the opioid receptors in the medulla and, as such, easily explains the anti-tussive effects of codeine.<xref ref-type="bibr" rid="article-19677.r17">[17]</xref></p>
      </sec>
      <sec id="article-19677.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Codeine is available in several formulations in combination with other agents, including acetaminophen, guaifenesin, promethazine, and pseudoephedrine. In pure form, codeine is available as oral tablets in 15, 30, and 60 mg strengths and as a 30 mg/5 mL solution. Codeine powder for compounding is available in 10 and 15 grams. Controlled release forms are available in some countries. Parenteral injections of codeine are discouraged.</p>
        <p>For the typical adult, an oral dose of codeine for analgesia ranges from 15 to 60 mg every 4&#x000a0;to 6 hours; the maximum dose is 360 mg per 24 hours. A 60 mg dose of codeine has a number needed to treat (NNT) of 12. Doses above 60 mg can be associated with increased&#x000a0;adverse effects and may not significantly improve analgesia.<xref ref-type="bibr" rid="article-19677.r1">[1]</xref> Initial dosing and titration can be individualized depending on the patient's health status, previous opioid exposure, attainment of therapeutic outcomes, and predicted or observed adverse events.<xref ref-type="bibr" rid="article-19677.r18">[18]</xref> Generally,&#x000a0;1 mg of codeine is equivalent to 0.15 morphine milliequivalents (MME).</p>
        <p>
<bold>Use in Specific Patient Population</bold>
</p>
        <p><bold>Hepatic impairment:</bold> According to manufacturer labeling, no studies have been conducted on patients with hepatic impairment. Hence&#x000a0;clinicians should prescribe codeine at a lower dose in these patients.</p>
        <p><bold>Renal impairment:</bold> The kidney is the major route of elimination, so pharmacokinetics is altered in patients with renal impairment. Consequently, clinicians should prescribe codeine at&#x000a0;a reduced dose&#x000a0;or with longer dosing intervals.</p>
        <p><bold>Pregnancy considerations:</bold> When used in pregnancy, unfavorable newborn outcomes such as premature birth, low birth weight, hypoxic-ischemic brain injury, and neonatal death may occur. Newborns may also develop neonatal abstinence syndrome. Suppose long-term codeine use is required in a pregnant patient. In that case, a clinician should counsel the patient on the risk of neonatal opioid withdrawal syndrome (box warning) and ensure adequate&#x000a0;management.<xref ref-type="bibr" rid="article-19677.r19">[19]</xref>&#x000a0;</p>
        <p><bold>Breastfeeding considerations:</bold> Maternal use of codeine during breastfeeding can cause infant drowsiness, central nervous system depression, and death. An increased sedation rate is noted in nursing infants of mothers taking codeine compared to non-opioid medications.<xref ref-type="bibr" rid="article-19677.r20">[20]</xref>&#x000a0;If the newborn shows sedation, problems in breastfeeding, or breathing difficulties, the mother should contact the clinician immediately. Given the increased susceptibility of newborns to the adverse effects of codeine, professional organizations, and regulatory agencies have advised against the use of codeine while breastfeeding. Non-narcotic analgesia is heavily encouraged for pregnant and breastfeeding mothers for these reasons.</p>
        <p><bold>Pediatric patients:</bold> Codeine is not indicated for monotherapy in pediatric patients.</p>
        <p><bold>Older patients:</bold> See hepatic and renal dosing.</p>
        <p><bold>Pharmacogenomic considerations (box warning):</bold>&#x000a0;Patients who are ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism gene (ultrarapid metabolizers) can metabolize codeine to morphine rapidly. Consequently, with standard doses of codeine, these patients may experience the symptoms of opioid overdose. Hence the FDA drug label for codeine reports that individuals who are ultrarapid metabolizers may have life-threatening or fatal respiratory depression at a therapeutic dose.<xref ref-type="bibr" rid="article-19677.r21">[21]</xref></p>
        <p>Although considerable heterogeneity exists concerning CYP2D6 enzyme capability within all ethnicities, Hispanic and White patients exhibit the highest CYP2D6 "ultrafast metabolizer" functionality.<xref ref-type="bibr" rid="article-19677.r21">[21]</xref></p>
      </sec>
      <sec id="article-19677.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Constipation is one of the most common adverse effects of codeine. Most patients report some&#x000a0;constipation following the initiation of therapy or increases in dose. With continued exposure, constipation remains a persistent harmful effect of the drug.<xref ref-type="bibr" rid="article-19677.r16">[16]</xref> Increased fluid intake and stool softeners are often recommended to patients to mitigate this unwanted effect. Nausea/vomiting is another common adverse effect, but it generally diminishes within days to weeks of continued codeine exposure. Anti-emetic therapies in both oral and rectal formulations are readily available for treatment.</p>
        <p>Clouded mentation or sedation following&#x000a0;codeine initiation tends to fade&#x000a0;over time. However, during initiation or dosage adjustments, patients should be counseled by their prescribing clinician about the drug's ability to affect their cognitive state, especially if that patient intends to drive or operate heavy machinery while on the medication until tolerance develops to this&#x000a0;adverse effect.&#x000a0;When&#x000a0;prescribed&#x000a0;codeine, patients should also receive counsel regarding the risk associated with exposure to other mind-altering substances. The concomitant use of codeine with other known sedatives, such as alcohol or&#x000a0;benzodiazepines, can significantly increase the risk of adverse and possibly dangerous effects. Naloxone availability can help as a specific antidote to reverse significant opioid overdose or CNS depression, even when these are secondary to concomitant use with other CNS depressing agents.</p>
        <p>Abuse, misuse, and addiction can occur, and patients should be appropriately counseled. Abrupt discontinuation in those who are physically dependent can lead to withdrawal reactions. Slow tapering (about 15% per week) is recommended for long-term users. Chronic use of controlled-released codeine is associated with hypogonadism and lower dehydroepiandrosterone sulfate levels.<xref ref-type="bibr" rid="article-19677.r16">[16]</xref> Patients have reported symptoms consistent with diminished sexual function, including decreased libido, fatigue, and/or impotence.</p>
        <p>Other common adverse effects include pruritis, urinary retention, hypersensitivity, blurred vision, bronchospasm, tremor, weakness, abdominal cramps, and pancreatitis. Patients with sleep apnea or other coexisting pulmonary disorders may be at a higher risk for respiratory depression, and doses must be initiated and titrated cautiously. When used in pregnancy, unfavorable newborn outcomes such as premature birth, low birth weight, hypoxic-ischemic brain injury, and neonatal death may occur. Newborns may also develop neonatal abstinence syndrome.<xref ref-type="bibr" rid="article-19677.r20">[20]</xref></p>
      </sec>
      <sec id="article-19677.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The following are contraindications to codeine:</p>
        <list list-type="bullet">
          <list-item>
            <p>FDA warning: Not to be used to treat pain or cough in patients aged less than 12</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity reaction to codeine or any component of the formulation</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Respiratory depression due to comorbid respiratory disorders</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Paralytic ileus</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intestinal obstruction</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Monoamine oxidase inhibitor use</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Known asthmatics taking codeine in an unmonitored setting</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Box Warning: Pediatric patients with obesity or conditions that can impair respiration, including those with a history of tonsillectomy or adenoidectomy.<xref ref-type="bibr" rid="article-19677.r22">[22]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Box Warning: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in respiratory depression, profound sedation, coma, and death. The FDA box warning has&#x000a0;been&#x000a0;associated with a decline in the number of patients with co-prescriptions of opioids and benzodiazepines; however, prescribers must be cognizant of this ever-present possibility.<xref ref-type="bibr" rid="article-19677.r23">[23]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19677.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring should include subjective as well as objective assessment via laboratory testing. Documentation of pain intensity, level of functioning, progress toward therapeutic goals, the presence of&#x000a0;adverse effects, and adherence to the therapy is recommended.<xref ref-type="bibr" rid="article-19677.r16">[16]</xref>&#x000a0;Generally, analgesia, adverse effects, activities of daily living, and abuse/addiction (the "4 As" of chronic opioid therapy) should be monitored in patients on chronic opioid therapy. Urine drug screening, pill counts, caregiver or family member encounters, and prescription monitoring program data can be helpful monitoring tools for patients on stable doses and with a low risk for adverse outcomes; monitoring every 3 to 6 months may be adequate. Weekly monitoring is a reasonable strategy for patients at high risk for abuse.<xref ref-type="bibr" rid="article-19677.r24">[24]</xref></p>
        <p>Monitoring with tools such as the Opioid Risk Tool (ORT) helps identify patients with an increased risk for misuse.&#x000a0;This tool helps to determine which chronic pain patients might benefit from other pain control modalities besides narcotics. Clinicians can use the Revised Opioid Risk Tool for patients with chronic nonmalignant pain (CNMP).<xref ref-type="bibr" rid="article-19677.r25">[25]</xref></p>
      </sec>
      <sec id="article-19677.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Deaths related to opioid toxicity have increased in the past decades, and a significant proportion of the increase derives from accidental overdoses. Opioid overdose is characteristically associated with a triad of abnormally slow respiration (apnea), decreased consciousness (coma), and pinpoint pupils (miosis). Codeine has a narrow therapeutic index, with a dose of 500&#x000a0;to 1000 mg usually proving fatal, though codeine-dependent individuals have been reported to use as much as 1536 mg daily.<xref ref-type="bibr" rid="article-19677.r2">[2]</xref></p>
        <p>This patient population is presumed to have a history of issues related to substance misuse/abuse, injection drug use, and chronic pain. These patterns&#x000a0;indicate that, in accidental deaths, any number of strategies are being used by patients who engage in codeine misuse, including supplementing codeine with prescribed pain medication, persistently escalating dosages without clinician approval, and selling/buying the drug outside of regulatory control. Therefore, a clear need exists for specialist intervention for&#x000a0;pain management in a complex patient population.<xref ref-type="bibr" rid="article-19677.r26">[26]</xref></p>
        <p>
<bold>Maximum Tolerated Dose</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Immediate-release preparation: 360 mg per day</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Controlled-release preparation: 600 mg per day</p>
          </list-item>
        </list>
        <p>Treatment of toxicity depends on both the symptoms and degree of&#x000a0;intoxication.&#x000a0;Toxicity involves symptomatic treatment (ie, enema for constipation) and definitive reversal with the opioid antagonist naloxone for life-threatening&#x000a0;adverse effects like respiratory depression. If the patient is physically dependent on opioids, the administration of opioid antagonists may precipitate acute withdrawal syndrome. Consequently, clinicians should prescribe opioid antagonists cautiously in patients with physical opioid dependence, and decreased dosages of antagonists should be considered for known dependent patients.</p>
      </sec>
      <sec id="article-19677.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing drug overdose requires an interprofessional team of&#x000a0;nurses, laboratory technologists, pharmacists, and clinicians in different specialties. While codeine is effective for its approved indications, without proper management, the morbidity and mortality from codeine overdose remain high. The moment the triage nurse has admitted a codeine overdose, the emergency department clinician is responsible for coordinating the care, which may include any number of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ordering blood and urine samples</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Monitoring the patient for signs and/or symptoms of respiratory depression, cardiac arrhythmias, and narcotic bowel syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Possibly performing any number of interventions designed to help limit the absorption of the drug in the body.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Consulting with the pharmacy about the use of activated charcoal and naloxone<xref ref-type="bibr" rid="article-19677.r27">[27]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Consulting with toxicology and nephrology regarding further management, up to and including dialysis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Imaging may be used to help evaluate the extent of ingestion (ie, suicide attempts involving ingestion of whole pill bottles)</p>
          </list-item>
        </list>
        <p>The management of codeine overdose does not stop in the emergency department or with the prescribing clinician.&#x000a0;When the patient is stabilized,&#x000a0;clinicians should try to ascertain how and why the patient overdosed. Consultation with a mental health counselor is advised to determine whether it was an intentional act of self-harm by the patient. Further, the possibility of addiction and withdrawal symptoms has to be considered. Only by working as an interprofessional team can the morbidity of codeine overdose decrease. Initial short-term data reveal that the use of naloxone can be life-saving.<xref ref-type="bibr" rid="article-19677.r28">[28]</xref> The long-term outcomes of detoxification and drug rehabilitation remain guarded since addiction is a chronic disease.<xref ref-type="bibr" rid="article-19677.r29">[29]</xref></p>
        <p>In 2018, the FDA implemented the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) program, designed to reduce the risk of misuse, abuse, addiction, overdose, and deaths due to prescription opioid analgesic use. As part of this program, drug companies with approved opioid analgesics provide unrestricted grants to accredited CE&#x000a0;clinicians to develop courses on how to safely and properly write and dispense these medications for common acute and chronic pain indications.</p>
        <p>All care team members are tasked with informing the rest of the interprofessional team if they note any concerns with patients using codeine, from therapeutic failure to possible misuse; open communication channels are crucial. Nursing staff should routinely assess for signs of overuse or toxicity and conduct interviews to ascertain appropriate administration. Pharmacists can observe for signs of "doctor shopping" and other at-risk behaviors and alert prescribers regarding their observations. They can also provide patient counsel and answer questions to help prevent accidental overdosing.</p>
        <p>All healthcare&#x000a0;professionals&#x000a0;are strongly recommended to complete the REMS education program and advise patients and their caregivers on the safe use and serious risks associated with opioids based on these parameters.<xref ref-type="bibr" rid="article-19677.r30">[30]</xref>&#x000a0;Similarly, the efficient use of the&#x000a0;Prescription Drug Monitoring Program (PDMP) can identify patients who are likely at risk of developing dependence and subsequent addiction to opioids.<xref ref-type="bibr" rid="article-19677.r24">[24]</xref>&#x000a0;Given the potential for misuse, clinicians must be aware of a patient exhibiting adverse effects of codeine use. Only with a collaborative, interprofessional, team-centered approach can the drug be safely used for its intended purpose without causing adverse outcomes.</p>
      </sec>
      <sec id="article-19677.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19677&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19677">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19677/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19677">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19677.s11">
        <title>References</title>
        <ref id="article-19677.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Verbeeck</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Should Codeine Still be Considered a WHO Essential Medicine?</article-title>
            <source>J Pharm Pharm Sci</source>
            <year>2021</year>
            <volume>24</volume>
            <fpage>329</fpage>
            <page-range>329-335</page-range>
            <pub-id pub-id-type="pmid">34192509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sobczak</surname>
                <given-names>&#x00141;</given-names>
              </name>
              <name>
                <surname>Gory&#x00144;ski</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological Aspects of Over-the-Counter Opioid Drugs Misuse.</article-title>
            <source>Molecules</source>
            <year>2020</year>
            <month>Aug</month>
            <day>27</day>
            <volume>25</volume>
            <issue>17</issue>
            <pub-id pub-id-type="pmid">32867117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x00106;eli&#x00107;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bach-Rojecky</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mer&#x00107;ep</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Soldo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petrak</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Bu&#x0010d;an</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Resolving Issues About Efficacy and Safety of Low-Dose Codeine in Combination Analgesic Drugs: A Systematic Review.</article-title>
            <source>Pain Ther</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>171</fpage>
            <page-range>171-194</page-range>
            <pub-id pub-id-type="pmid">32172479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <article-title>Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy.</article-title>
            <source>Pain Suppl</source>
            <year>1986</year>
            <volume>3</volume>
            <fpage>S1</fpage>
            <page-range>S1-226</page-range>
            <pub-id pub-id-type="pmid">3461421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Marchand</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Arg&#x000e1;ez</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <source>Codeine for Acute Extremity Pain [Internet]</source>
            <publisher-name>Canadian Agency for Drugs and Technologies in Health</publisher-name>
            <publisher-loc>Ottawa (ON)</publisher-loc>
            <year>2021</year>
            <month>01</month>
            <pub-id pub-id-type="pmid">34185448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aldington</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wiffen</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2015</year>
            <month>Sep</month>
            <day>28</day>
            <volume>2015</volume>
            <issue>9</issue>
            <fpage>CD008659</fpage>
            <pub-id pub-id-type="pmid">26414123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Passik</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Kirsh</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>The need to identify predictors of aberrant drug-related behavior and addiction in patients being treated with opioids for pain.</article-title>
            <source>Pain Med</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>186</fpage>
            <page-range>186-9</page-range>
            <pub-id pub-id-type="pmid">12873265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arinze</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>de Roos</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Karimi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Verhamme</surname>
                <given-names>KMC</given-names>
              </name>
              <name>
                <surname>Stricker</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Brusselle</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and incidence of, and risk factors for chronic cough in the adult population: the Rotterdam Study.</article-title>
            <source>ERJ Open Res</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">32337212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>On</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Updates in treatment of adults with chronic cough.</article-title>
            <source>Am J Manag Care</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>11 Suppl</issue>
            <fpage>S239</fpage>
            <page-range>S239-S245</page-range>
            <pub-id pub-id-type="pmid">33058686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matthys</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bleicher</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bleicher</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough.</article-title>
            <source>J Int Med Res</source>
            <year>1983</year>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>92</fpage>
            <page-range>92-100</page-range>
            <pub-id pub-id-type="pmid">6852361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silber</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Buchfuhrer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Earley</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Manconi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Winkelman</surname>
                <given-names>JW</given-names>
              </name>
              <collab>Scientific and Medical Advisory Board of the Restless Legs Syndrome Foundation</collab>
            </person-group>
            <article-title>The Management of Restless Legs Syndrome: An Updated Algorithm.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>96</volume>
            <issue>7</issue>
            <fpage>1921</fpage>
            <page-range>1921-1937</page-range>
            <pub-id pub-id-type="pmid">34218864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmer</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Holdsworth</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea.</article-title>
            <source>Gastroenterology</source>
            <year>1980</year>
            <month>Dec</month>
            <volume>79</volume>
            <issue>6</issue>
            <fpage>1272</fpage>
            <page-range>1272-5</page-range>
            <pub-id pub-id-type="pmid">7002706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Crosby</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Yip</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Maguire</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>A Review of the Important Role of <italic>CYP2D6</italic> in Pharmacogenomics.</article-title>
            <source>Genes (Basel)</source>
            <year>2020</year>
            <month>Oct</month>
            <day>30</day>
            <volume>11</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">33143137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hockings</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Pasternak</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Erwin</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenomics: An evolving clinical tool for precision medicine.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>87</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-99</page-range>
            <pub-id pub-id-type="pmid">32015062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Findlay</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Fowle</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Butz</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Weatherley</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Welch</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Posner</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Comparative disposition of codeine and pholcodine in man after single oral doses.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1986</year>
            <month>Jul</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-71</page-range>
            <pub-id pub-id-type="pmid">3741728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edinoff</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sauce</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Causey</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Imani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Moradi Moghadam</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Full Opioid Agonists and Tramadol: Pharmacological and Clinical Considerations.</article-title>
            <source>Anesth Pain Med</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>e119156</fpage>
            <pub-id pub-id-type="pmid">34692448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pathan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Basic opioid pharmacology: an update.</article-title>
            <source>Br J Pain</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-6</page-range>
            <pub-id pub-id-type="pmid">26516461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Portenoy</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Rauck</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shoemaker</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain.</article-title>
            <source>J Pain</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>7</volume>
            <issue>8</issue>
            <fpage>583</fpage>
            <page-range>583-91</page-range>
            <pub-id pub-id-type="pmid">16885015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Broussard</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Reefhuis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jann</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Riehle-Colarusso</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Honein</surname>
                <given-names>MA</given-names>
              </name>
              <collab>National Birth Defects Prevention Study</collab>
            </person-group>
            <article-title>Maternal treatment with opioid analgesics and risk for birth defects.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>204</volume>
            <issue>4</issue>
            <fpage>314.e1</fpage>
            <page-range>314.e1-11</page-range>
            <pub-id pub-id-type="pmid">21345403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ito</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>58 Suppl 10</volume>
            <fpage>S151</fpage>
            <page-range>S151-S163</page-range>
            <pub-id pub-id-type="pmid">30248201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dean</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Codeine Therapy and <italic>CYP2D6</italic> Genotype</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Pratt</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esquivel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kattman</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Malheiro</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <source>Medical Genetics Summaries [Internet]</source>
            <publisher-name>National Center for Biotechnology Information (US)</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2012</year>
            <month>9</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">28520350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuehn</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>FDA: No codeine after tonsillectomy for children.</article-title>
            <source>JAMA</source>
            <year>2013</year>
            <month>Mar</month>
            <day>20</day>
            <volume>309</volume>
            <issue>11</issue>
            <fpage>1100</fpage>
            <pub-id pub-id-type="pmid">23512037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Olfson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Opioid and Benzodiazepine Coprescribing in the United States Before and After US Food and Drug Administration Boxed Warning.</article-title>
            <source>JAMA Psychiatry</source>
            <year>2019</year>
            <month>Nov</month>
            <day>01</day>
            <volume>76</volume>
            <issue>11</issue>
            <fpage>1208</fpage>
            <page-range>1208-1210</page-range>
            <pub-id pub-id-type="pmid">31532463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henry</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tseregounis</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Shev</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Gasper</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Tancredi</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Cerd&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>BDL</given-names>
              </name>
              <name>
                <surname>Wintemute</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Using Prescription Drug Monitoring Program Data to Assess Likelihood of Incident Long-Term Opioid Use: a Statewide Cohort Study.</article-title>
            <source>J Gen Intern Med</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>12</issue>
            <fpage>3672</fpage>
            <page-range>3672-3679</page-range>
            <pub-id pub-id-type="pmid">33742304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheatle</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Compton</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Dhingra</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wasser</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Development of the Revised Opioid Risk Tool to Predict Opioid Use Disorder in Patients with Chronic Nonmalignant Pain.</article-title>
            <source>J Pain</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>20</volume>
            <issue>7</issue>
            <fpage>842</fpage>
            <page-range>842-851</page-range>
            <pub-id pub-id-type="pmid">30690168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schifano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chiappini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miuli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mosca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Santovito</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Corkery</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Guirguis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pettorruso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Giannantonio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martinotti</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants.</article-title>
            <source>Front Psychiatry</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>657397</fpage>
            <pub-id pub-id-type="pmid">34025478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hedberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bui</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Livingston</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Van Otterloo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Integrating Public Health and Health Care Strategies to Address the Opioid Epidemic: The Oregon Health Authority's Opioid Initiative.</article-title>
            <source>J Public Health Manag Pract</source>
            <year>2019</year>
            <season>May/Jun</season>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>214</fpage>
            <page-range>214-220</page-range>
            <pub-id pub-id-type="pmid">30048336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Losby</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hyatt</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Kanter</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Safer and more appropriate opioid prescribing: a large healthcare system's comprehensive approach.</article-title>
            <source>J Eval Clin Pract</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>1173</fpage>
            <page-range>1173-1179</page-range>
            <pub-id pub-id-type="pmid">28707421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sederer</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Marino</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Ending the Opioid Epidemic by Changing the Culture.</article-title>
            <source>Psychiatr Q</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>89</volume>
            <issue>4</issue>
            <fpage>891</fpage>
            <page-range>891-895</page-range>
            <pub-id pub-id-type="pmid">29961915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19677.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duensing</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Twillman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ziegler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cepeda</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kern</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Salas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wedin</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016-2018.</article-title>
            <source>J Pain Res</source>
            <year>2020</year>
            <volume>13</volume>
            <fpage>2431</fpage>
            <page-range>2431-2442</page-range>
            <pub-id pub-id-type="pmid">33061558</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
